BRPI0713951B8 - derivados de quinazolina, e composição farmacêutica - Google Patents

derivados de quinazolina, e composição farmacêutica

Info

Publication number
BRPI0713951B8
BRPI0713951B8 BRPI0713951A BRPI0713951A BRPI0713951B8 BR PI0713951 B8 BRPI0713951 B8 BR PI0713951B8 BR PI0713951 A BRPI0713951 A BR PI0713951A BR PI0713951 A BRPI0713951 A BR PI0713951A BR PI0713951 B8 BRPI0713951 B8 BR PI0713951B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
compounds
quinazoline derivatives
meanings
beta
Prior art date
Application number
BRPI0713951A
Other languages
English (en)
Inventor
Reber Jean-Louis
Lohse Olivier
Monnier Stéphanie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0713951A2 publication Critical patent/BRPI0713951A2/pt
Publication of BRPI0713951B1 publication Critical patent/BRPI0713951B1/pt
Publication of BRPI0713951B8 publication Critical patent/BRPI0713951B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composto derivado de quinazolina e composição farmacêutica compreendendo o mesmo. a presente invenção refere-se a compostos de fórmula i em forma de sal ou solvato, em que w, rx, ry,r1, r2, r3, r4, r5, r6 e r7 e a têm os significados como indicado no relatório descritivo, são úteis para tratar doenças mediadas pelo (beta)2-adrenorreceptor. as composições farmacêuticas que contêm os compostos e processos para preparar os compostos são da mesma forma descritos.
BRPI0713951A 2006-06-30 2007-07-02 derivados de quinazolina, e composição farmacêutica BRPI0713951B8 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613159.3 2006-06-30
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613158.5 2006-06-30
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613160.1 2006-06-30
GB0613156.9 2006-06-30
EP06117129.4 2006-07-13
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions
PCT/EP2007/056632 WO2008000839A1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Publications (3)

Publication Number Publication Date
BRPI0713951A2 BRPI0713951A2 (pt) 2012-12-04
BRPI0713951B1 BRPI0713951B1 (pt) 2019-08-13
BRPI0713951B8 true BRPI0713951B8 (pt) 2021-05-25

Family

ID=38610531

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713951A BRPI0713951B8 (pt) 2006-06-30 2007-07-02 derivados de quinazolina, e composição farmacêutica

Country Status (27)

Country Link
US (2) US8198450B2 (pt)
EP (1) EP2044025B1 (pt)
JP (1) JP5253392B2 (pt)
KR (1) KR101402398B1 (pt)
CN (1) CN101479245B (pt)
AU (1) AU2007264946B2 (pt)
BR (1) BRPI0713951B8 (pt)
CA (1) CA2654801C (pt)
CY (3) CY1113733T1 (pt)
DK (1) DK2044025T3 (pt)
ES (1) ES2396987T3 (pt)
FR (2) FR20C1054I1 (pt)
HK (1) HK1127597A1 (pt)
HR (1) HRP20121074T1 (pt)
HU (2) HUS2000043I1 (pt)
IL (1) IL195796A (pt)
LT (2) LTC2044025I2 (pt)
MA (1) MA30540B1 (pt)
MX (1) MX2008016542A (pt)
MY (1) MY150468A (pt)
NO (3) NO341709B1 (pt)
NZ (1) NZ573292A (pt)
PL (1) PL2044025T3 (pt)
PT (1) PT2044025E (pt)
SI (1) SI2044025T1 (pt)
WO (1) WO2008000839A1 (pt)
ZA (1) ZA200809948B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500738A (ja) 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
WO2009031011A2 (en) 2007-09-05 2009-03-12 Pfizer Limited Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
KR102074543B1 (ko) 2013-03-14 2020-02-06 노파르티스 아게 분무-블렌딩을 통한 분무-건조 제제의 탈무정형화
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
WO2017055506A1 (en) 2015-09-29 2017-04-06 Laboratorios Lesvi, S.L. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl] -8-hydroxy-1h-quinolin-2-one l-tartrate
CN110724095B (zh) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 一种茚达特罗乙酸盐的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (ja) * 1991-08-29 1993-08-10 Yamamoto Chem Inc ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20050211A1 (es) 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
US7745462B2 (en) 2003-04-04 2010-06-29 Novartis Ag Quinoline-2-one derivatives for the treatment of airways diseases
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
MX2007011600A (es) 2005-03-21 2007-12-07 Lilly Co Eli Compuestos de imidazopiridazina.
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors

Also Published As

Publication number Publication date
CY2020041I1 (el) 2021-03-12
DK2044025T3 (da) 2013-01-14
NZ573292A (en) 2011-03-31
NO20090312L (no) 2009-01-28
US20120316142A1 (en) 2012-12-13
CY2020038I2 (el) 2021-03-12
EP2044025A1 (en) 2009-04-08
IL195796A0 (en) 2009-09-01
NO2020041I1 (no) 2020-11-23
FR20C1054I1 (fr) 2020-12-25
CY2020038I1 (el) 2021-03-12
NO2020044I1 (no) 2020-12-07
HUS2000053I1 (hu) 2020-12-28
KR101402398B1 (ko) 2014-06-03
CN101479245B (zh) 2013-05-22
JP2009541455A (ja) 2009-11-26
LTC2044025I2 (lt) 2022-10-10
LTPA2020535I1 (lt) 2020-12-28
LTPA2020538I1 (lt) 2021-01-11
HK1127597A1 (en) 2009-10-02
HRP20121074T1 (hr) 2013-01-31
HUS2000043I1 (hu) 2020-12-28
US20090325912A1 (en) 2009-12-31
WO2008000839A1 (en) 2008-01-03
BRPI0713951A2 (pt) 2012-12-04
ZA200809948B (en) 2009-05-25
US8198450B2 (en) 2012-06-12
MA30540B1 (fr) 2009-06-01
AU2007264946B2 (en) 2011-01-20
IL195796A (en) 2016-03-31
AU2007264946A1 (en) 2008-01-03
FR20C1063I1 (fr) 2021-01-22
PT2044025E (pt) 2012-12-17
ES2396987T3 (es) 2013-03-01
PL2044025T3 (pl) 2013-02-28
EP2044025B1 (en) 2012-10-03
MY150468A (en) 2014-01-30
CA2654801A1 (en) 2008-01-03
NO341709B1 (no) 2018-01-02
KR20090023651A (ko) 2009-03-05
CY1113733T1 (el) 2016-06-22
BRPI0713951B1 (pt) 2019-08-13
CY2020041I2 (el) 2021-03-12
SI2044025T1 (sl) 2013-01-31
MX2008016542A (es) 2009-01-19
JP5253392B2 (ja) 2013-07-31
CN101479245A (zh) 2009-07-08
CA2654801C (en) 2014-08-19

Similar Documents

Publication Publication Date Title
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BRPI0916995B8 (pt) compostos orgânicos, seu uso, e composição farmacêutica
BR112012010186B8 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
MX2010006421A (es) Compuestos organicos.
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
BRPI0918750B8 (pt) derivado de 2-carboxamida cicloamino ureia, seu uso e sua composição farmacêutica
BRPI0713544B8 (pt) estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia
BRPI0915084B8 (pt) composto, e, composição farmacêutica
BRPI0713951B8 (pt) derivados de quinazolina, e composição farmacêutica
ATE522249T1 (de) Organische verbindungen
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BR112013000868A2 (pt) derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
WO2007140385A3 (en) Thiazole compounds as cannabinoid receptor ligands and uses thereof
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
BRPI0410238A (pt) compostos orgánicos
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
BRPI0519208A2 (pt) derivados de pirrolinÍdio como receptores muscarÍnicos m3
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
BR112021018238A2 (pt) Derivados de azolopiridina macrocíclicos como moduladores de eed e prc2
BR112014029439A2 (pt) derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/07/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF